# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor str...
Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2025 sales of $165.000 million-$175.000 million vs $159.818 million analyst estimate.
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate ...
Craig-Hallum analyst Chase Knickerbocker maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price tar...